Chronic use of triazolam: the effects on the sleep patterns of insomniacs
- PMID:6104615
- DOI: 10.1177/030006058000800308
Chronic use of triazolam: the effects on the sleep patterns of insomniacs
Abstract
The present study was designed to evaluate the effects of triazolam 0.5 mg on the sleep of insomniac patients when given for 3 weeks. The results showed that both acute and chronic triazolam administration are effective in decreasing sleep latency, increasing sleep duration, increasing sleep efficiency and decreasing total wake time without producing major effects on sleep staging. Sleep Stages 1 and 2 were significantly altered by drug treatment but in a positive direction. This change is primarily attributable to the significant decrease in sleep onset. Deep sleep and REM were not significantly changed during triazolam treatment nor was there any evidence of REM rebound after discontinuation of the medication. It was noted that some of the sleep parameters measured shifted toward baseline measures in the first night after triazolam treatment was terminated. However, the total recovery period recorded (7 days) showed the quality and quantity of sleep obtained to be improved over baseline measures. The recovery data compared favourably with those improvements noted during chronic administration of triazolam. It was also found that 3 weeks of triazolam 0.5 mg usage did not result in tolerance to its hypnotic properties. Thus, triazolam maintains its hypnotic effectiveness throughout 3 weeks of administration.
Similar articles
- Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia.Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS.Pakes GE, et al.Drugs. 1981 Aug;22(2):81-110. doi: 10.2165/00003495-198122020-00001.Drugs. 1981.PMID:6114852Review.
- Intermediate use of triazolam: a sleep laboratory study.Roth T, Kramer M, Lutz T.Roth T, et al.J Int Med Res. 1976;4(1):59-63. doi: 10.1177/030006057600400109.J Int Med Res. 1976.PMID:16793Clinical Trial.
- Comparative efficacy of triazolam, flurazepam and placebo in out-patients insomniacs.Bowen AJ.Bowen AJ.J Int Med Res. 1978;6(4):337-42. doi: 10.1177/030006057800600412.J Int Med Res. 1978.PMID:28989Clinical Trial.
- Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long- versus a short-half-life benzodiazepine (quazepam versus triazolam).Saletu B, Anderer P, Brandstätter N, Frey R, Grünberger J, Klösch G, Mandl M, Wetter T, Zeitlhofer J.Saletu B, et al.Neuropsychobiology. 1994;29(2):69-90. doi: 10.1159/000119067.Neuropsychobiology. 1994.PMID:8170529Clinical Trial.
- Rebound insomnia: a critical review.Gillin JC, Spinweber CL, Johnson LC.Gillin JC, et al.J Clin Psychopharmacol. 1989 Jun;9(3):161-72.J Clin Psychopharmacol. 1989.PMID:2567741Review.
Cited by
- Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia.Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS.Pakes GE, et al.Drugs. 1981 Aug;22(2):81-110. doi: 10.2165/00003495-198122020-00001.Drugs. 1981.PMID:6114852Review.
- An assessment of short-acting hypnotics.Mendelson WB, Jain B.Mendelson WB, et al.Drug Saf. 1995 Oct;13(4):257-70. doi: 10.2165/00002018-199513040-00005.Drug Saf. 1995.PMID:8573298Review.
- Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?Vinkers CH, Olivier B.Vinkers CH, et al.Adv Pharmacol Sci. 2012;2012:416864. doi: 10.1155/2012/416864. Epub 2012 Mar 29.Adv Pharmacol Sci. 2012.PMID:22536226Free PMC article.
- Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: A narrative review.Palagini L, Bianchini C.Palagini L, et al.Front Neurosci. 2022 Jul 29;16:893015. doi: 10.3389/fnins.2022.893015. eCollection 2022.Front Neurosci. 2022.PMID:35968380Free PMC article.Review.
- Effects of triazolam (0.5 mg) on sleep, performance, memory, and arousal threshold.Spinweber CL, Johnson LC.Spinweber CL, et al.Psychopharmacology (Berl). 1982;76(1):5-12. doi: 10.1007/BF00430746.Psychopharmacology (Berl). 1982.PMID:6123129Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical